Potent, orally active dipeptidyl peptidase (DPP)-IV inhibitor (Ki
= 11 nM, IC50
= 14 nM) that displays > 15 000-fold selectivity over DPP-II and a range of proline-cleaving proteases. Exhibits antidiabetic activity in vivo
; improves glucose tolerance, increases glucagon-like peptide 1 (GLP-1) and insulin levels, augments insulin secretion and GLUT2 levels, and reduces (preserves) islet size.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV.
Hughes et al.
Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice.
Reimer et al.
Dipeptidyl peptidase IV inhibitor NVP-DPP728 ameliorates early insulin response and glucose tolerance in aged rats but not in aged Fischer 344 rats lacking its enzyme activity.
Mitani et al.
The citations listed below are publications that use Tocris products. Selected citations for NVP DPP 728 dihydrochloride include:
Showing Results 1 - 1 of 1